XOMA Royalty has reported its Q3 2025 financial results and highlighted key business achievements, including securing royalty interests in early-stage assets through an acquisition. This strategy focuses on generating revenue from royalty streams, which can provide stable income. Business development wins, like securing new royalty interests, are positive indicators of growth potential. Investors in the biotech and pharmaceutical sectors may find XOMA’s royalty-focused model attractive.